2026-11-20 04:24:09
Belzutifan’s originator is Merck’s Welireg, born at Peloton Therapeutics, acquired in 2019, FDA-approved August 2021 for VHL-related tumors.
2026-11-18 07:27:07
Pralsetinib (GAVRETO) is a selective RET inhibitor for RET fusion-positive NSCLC and RET-altered thyroid cancers. Learn how it works, who it fits, and why genomic testing comes first.
2026-11-17 03:22:48
Sotorasib for KRAS G12C non-small cell lung cancer often causes diarrhea, mostly grade 1–2. This concise guide covers onset patterns, home antidiarrheal use, oral rehydration, low-residue diet, urgent warning signs and dose modification. All decisions must follow the prescribing information and physician assessment.
2026-11-17 03:09:02
Hypertension occurs in about 20% of patients receiving pralsetinib for non-small cell lung cancer, mostly mild to moderate. This article covers onset patterns, home blood pressure monitoring, antihypertensive selection, dose adjustment criteria and lifestyle measures. All treatment decisions should follow the prescribing information and physician evaluation.
2026-11-16 03:10:55
Tucatinib is an oral selective HER2 tyrosine kinase inhibitor used with trastuzumab ± capecitabine for selected HER2-positive breast cancer, including brain metastases, and with trastuzumab for RAS wild-type HER2-positive colorectal cancer. This article simplifies indications, 300mg twice-daily dosing, HER2CLIMB/MOUNTAINEER outcomes, diarrhea/hepatotoxicity management and procurement safety.
2026-11-16 02:36:53
Avapritinib (Ayvakit) is a potent PDGFRα/c‑Kit inhibitor approved for adults with PDGFRα exon 18 mutant unresectable or metastatic GIST, advanced systemic mastocytosis (AdvSM) and indolent systemic mastocytosis (ISM). This article summarizes complete administration guidelines, risk monitoring, dose modification, special population use and drug interactions.
2026-11-13 02:50:29
Animal data show embryo-fetal lethality and teratogenicity with daraxonrasib; no human pregnancy data exist. Use effective contraception during therapy and for 1 week after the last dose, and avoid breastfeeding.
2026-11-13 02:28:49
Afatinib for EGFR-mutant NSCLC commonly causes diarrhea, rash, stomatitis, and paronychia; severe ILD, hepatotoxicity, and dehydration require prompt care and physician-led dose changes.
2026-11-13 02:24:34
Capmatinib is an oral MET kinase inhibitor for adults with metastatic NSCLC confirmed to have MET exon 14 skipping; standard dosing is 400 mg twice daily.
2026-11-13 02:18:40
Ibrutinib treats CLL/SLL, but most patients need watchful waiting after diagnosis. Treatment starts only upon iwCLL active disease criteria; transient lymphocytosis may occur early.
2026-11-12 02:34:57
Covers elacestrant’s FDA indication and EMERALD efficacy, factors affecting approval timelines in other regions, and endocrine follow-up for ESR1-mutant breast cancer during the waiting period.
2026-11-12 02:28:01
Review the effects of stiripentol on appetite, weight, height and cognitive outcomes in pediatric patients with Dravet syndrome, covering growth monitoring, nutritional support, dose adjustment and scheduled developmental assessments.